Examination about the confirmation of the efficacy at change from brand-name sustained-release oxycodone to generic sustained-release oxycodone.

Examination about the confirmation of the efficacy at change from brand-name sustained-release oxycodone to generic sustained-release oxycodone. - Examination about the confirmation of the efficacy at change from brand-name sustained-release oxycodone to generic sustained-release oxycodone.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026192

Enrollment

Registered

2017-02-22

Start date

2014-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

Taking brand-name sustained-release oxycodone for two weeks and generic sustained-release oxycodone for two weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Taking brand-name sustained-release oxycodone more than two weeks before entry, Agreement of the doctor

Exclusion criteria

Exclusion criteria: Change in basal dose within two weeks before the entry, Increases or decreases in frequency of the rescue dose within two weeks before the entry, Judged inappropriate by the doctor

Design outcomes

Primary

Measure	Time frame
Numeric rating scale of cancer pain	—

Secondary

Measure	Time frame
Onset of side effect	—

Countries

Japan

Contacts

Public ContactJunko Nakanishi

Mitoyo General Hospital Department of pharmaceutical services

junko-ph@mitoyo-hosp.jp0875-52-3366

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026